Medically reviewed by
Dr. Haritha Mikkilineni, MD
SS-31 (Elamipretide) Peptide Therapy in Southlake, TX
SS-31 (Elamipretide) is investigational for cellular energy, and Dr. Mikki says so plainly before she doses it in Southlake. It is a peptide that targets the mitochondria. Dosing is supervised, and it is sourced from licensed compounding pharmacies.
- Google 4.8★
- Yelp 5.0★
Why Medrein for SS-31
Every peptide protocol at Medrein is prescribed and overseen by Dr. Mikki, our medical director, who spent 15 years in emergency medicine before founding the practice. Nothing is dispensed without a consultation with her.
SS-31 works at the mitochondrial membrane
SS-31 is a tetrapeptide that concentrates in the inner mitochondrial membrane and binds cardiolipin, a lipid central to energy production. It is studied for its effect on ATP output and oxidative stress. SS-31 sits in Medrein's energy peptides group alongside NAD+ and MOTS-C.
What SS-31 therapy involves
What SS-31 is used for
SS-31 is the protector among the energy peptides. Where NAD+ supplies a coenzyme and MOTS-C carries a metabolic signal, SS-31 works on the membrane where energy is actually produced. It remains under clinical study, and Dr. Mikki states that before she recommends it. Results may vary.
Mitochondrial health
The core of it. SS-31 penetrates mitochondrial membranes and is studied for protecting them from the oxidative damage that accumulates with age and illness.
Energy output
By targeting cardiolipin in the inner membrane and optimizing electron transport chain function, it is studied for its effect on ATP production, the cell’s actual energy currency.
Oxidative stress
It is studied for reducing free radicals, the by-product of energy production that damages the machinery producing it.
Cardiovascular protection
Heart muscle is dense with mitochondria, which is why cardiovascular protection appears among the benefit areas in the research Dr. Mikki works from.
Neuroprotection and cognition
Neurons are also mitochondria-heavy. Neuroprotective and cognitive benefits are among the areas under study for this peptide.
Performance and aging
Patients pursue SS-31 for energy, endurance and the longevity end of mitochondrial health. It is investigational for these uses, and Dr. Mikki will say where the evidence stops.
What SS-31 treatment looks like
The evidence conversation happens at the start, not as a footnote. These are the four stages.
Consultation and assessment
Dr. Mikki reviews your health status, your energy picture and your goals, and sets out what the research on SS-31 does and does not yet show before anything is prescribed.
Designing your plan
She decides whether SS-31 alone fits or whether it belongs alongside NAD+ and MOTS-C, and writes the prescription. A licensed compounding pharmacy supplies the peptide.
Self-administration at home
SS-31 is given by subcutaneous injection at home. Dr. Mikki sets the dose and the schedule, and the technique is shown before you leave the clinic.
Follow-up and adjustment
Reduced oxidative stress is described in the first week or two; comprehensive mitochondrial optimization is measured across eight to twelve weeks or beyond. She adjusts on non-response.
A different route to cellular energy
SS-31 acts on the membrane where energy is produced, which is a different job from a coenzyme or a signaling peptide. It is still under clinical study, so Dr. Mikki states what the evidence shows before recommending it. Patients comparing the signaling route often ask about MOTS-C at the same visit.
| Feature | SS-31 (Medrein) | Signaling Peptide | No Treatment |
|---|---|---|---|
| Targets the inner mitochondrial membrane | Included | Not included | Not included |
| Binds cardiolipin to support energy output | Included | Not included | Not included |
| Physician-supervised, compounded by a licensed pharmacy | Included | Included | Not included |
| Evidence status stated before recommending | Included | Varies | Not included |
Safety, monitoring and honest limits
Dr. Mikki describes an excellent safety profile for SS-31 when it is properly prescribed and monitored. Its FDA status sits beside that, at the same size: approved only for Barth syndrome, and off-label for energy. For most people reading this, that is the more important half.
Why this is supervised care
- SS-31 is described as having an excellent safety profile when properly prescribed and monitored.
- It is compounded by a licensed pharmacy on Dr. Mikki’s prescription.
- Candidacy, current medications and health status are reviewed before it is prescribed.
- The dose is set conservatively and adjusted against your response at follow-up.
- Dr. Mikki, a board-certified ER physician, sets and reviews every treatment plan herself.
Limits and what to expect
- Not recommended during pregnancy or while breastfeeding.
- SS-31 is approved by the FDA only for Barth syndrome, so using it for energy is off-label. The research is promising but still developing, and Dr. Mikki makes that clear during consultation.
- Nothing is immediate. Early change is described in the first week or two, fuller optimization across eight to twelve weeks or beyond.
- It sits at the premium end of the energy peptides on cost.
- It supports cellular energy; it does not diagnose or treat the medical causes of fatigue.
Who SS-31 is for
Dr. Mikki confirms candidacy at consultation and will point you elsewhere when the fit is wrong. Patients comparing the signalling route usually ask about MOTS-C at the same visit, and the wider energy peptides category sets all three side by side.
A good fit
- Persistent fatigue and brain fog where the mitochondrial angle is worth exploring.
- Patients already on an energy regimen who want the protective piece added.
- An interest in longevity and mitochondrial health beyond a quick energy boost.
- People who want the evidence stated honestly before they decide.
Not the right treatment
- Pregnancy or breastfeeding.
- Anyone who wants a treatment with settled, large-scale human evidence behind it. SS-31 is not there yet.
- Fatigue with an untreated medical cause, which needs finding first.
- Anyone expecting a result inside a week.
Three things worth knowing before you book
SS-31 is the premium-priced peptide of the three energy molecules, so ask for your own figure at consultation; package pricing exists and HSA and FSA apply in many cases. It combines with NAD+ and MOTS-C, with growth-hormone peptides such as CJC-1295 and Ipamorelin, with IV nutrient therapy and with hormone optimization. And for energy it is off-label, so Dr. Mikki will tell you where the evidence stops instead of talking past it. Results may vary.
Why patients choose SS-31 at Medrein
These reflect common patient sentiment rather than verbatim quotes, and individual results vary.
What I noticed with Dr. Mikki was how careful she was about what SS-31 is and is not. She explained what it targets, that it is still being studied, and that she would start me low and watch how I responded. She did not oversell it. I trusted the plan because she was honest about the science.
She told me straight where the evidence is strong and where it is still early. No hype.
SS-31 peptide FAQs
What is SS-31 (Elamipretide)?
SS-31, also known as Elamipretide, is a mitochondria-targeting tetrapeptide. It concentrates in the inner mitochondrial membrane and binds cardiolipin, a lipid central to how mitochondria produce energy. Dr. Mikki supervises the treatment and sources it from a licensed compounding pharmacy.
What do patients use SS-31 for?
Patients pursue SS-31 for cellular energy, recovery, and support against oxidative stress. It is studied for its effect on ATP production at the mitochondrial membrane. These are areas of active research, not guaranteed outcomes, and results may vary by individual.
How is SS-31 different from MOTS-C or NAD+?
SS-31, MOTS-C and NAD+ act at different points in the same mitochondrial pathway: SS-31 stabilizes the inner membrane, MOTS-C sends a metabolic signal such as AMPK activation, and NAD+ supplies the coenzyme used directly in energy production. All three sit in Medrein’s energy and mitochondrial peptide group. Dr. Mikki explains which fits your goals at consultation, and she commonly prescribes the three together instead of choosing between them.
Is SS-31 FDA-approved?
Only for one rare condition. In 2025 the FDA granted SS-31 (Elamipretide) accelerated approval, as Forzinity, for Barth syndrome, a rare genetic disease. It is not approved for energy, endurance or longevity, so that use is off-label. Dr. Mikki is transparent about that status and about what the current evidence supports before recommending it.
Is SS-31 safe, and who supervises it?
Yes, SS-31 carries an excellent safety profile when properly prescribed and monitored, and that supervision comes directly from Dr. Haritha Mikkilineni, MD, a board-certified physician. She confirms candidacy, sets a conservative starting dose, and follows up on how you tolerate it. The peptide is compounded by a reputable pharmacy, not sourced from unverified suppliers.
How quickly does SS-31 work?
Reduced oxidative stress is described in the first week or two, with comprehensive mitochondrial optimization across eight to twelve weeks or beyond. It is not a same-day change, and results may vary.
Can SS-31 be combined with other treatments?
Yes, SS-31 is commonly run alongside NAD+ and MOTS-C, growth-hormone peptides such as CJC-1295 and Ipamorelin, repair peptides such as TB-500 and BPC-157, IV nutrient therapy and hormone optimization. Every combination is reviewed against your medication list at consultation.
How much does SS-31 cost, and how long do I stay on it?
Courses typically run four to eight weeks for a short course, twelve to sixteen weeks for a medium course, or long-term with maintenance dosing, depending on your goals. Cost sits at the premium end of the energy peptides, and the exact figure depends on your plan and its duration, so Dr. Mikki quotes it at consultation instead of publishing a range. Package pricing exists, and HSA and FSA apply in many cases.
Is SS-31 right for you?
Dr. Mikki reviews your energy goals, states what the evidence shows, confirms candidacy, and sets a conservative starting dose.
Board-certified MD · NPI 1891947438 · Licensed in TX and NM · 4.8★ from 131 Google reviews